Assessing the dose of regadenoson required to transiently alter blood-brain barrier integrity in patients with infiltrating gliomas.

ABSTRACT:

Background

The blood-brain barrier (BBB) severely limits the delivery of therapeutic agents to the brain. Regadenoson, a Food and Drug Administration-approved adenosine A2 agonist, transiently increases BBB permeability in rodents to a 70 kDa dextran. This multi-institutional, NIH-funded study examined regadenoson's ability to transiently alter BBB permeability in patients with gliomas.

Methods

Adults with supratentorial gliomas at low risk for regadenoson complications were treated with 1 of the 7 dose levels known to be safe in humans. Successful BBB disruption was defined as a 10-fold increase in vascular permeability (K ^trans ) relative to historic benchmarks. This was assessed by dynamic contrast-enhanced perfusion on magnetic resonance imaging

SUBMITTER: Grossman SA 

PROVIDER: S-EPMC11992616 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature